etofylline clofibrate: whole issue; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 41109 |
| CHEMBL ID | 1318939 |
| CHEBI ID | 135681 |
| SCHEMBL ID | 49272 |
| MeSH ID | M0092257 |
| Synonym |
|---|
| AC-12772 |
| 1-(theophyllin-7-yl)athyl-2-(2-(p-chlorphenoxy)-2-methylpropionat |
| mls003115174 , |
| 1-(theophyllin-7-yl)ethyl-2-(2-(p-chlorophenoxy)-2-methylpropionate |
| nsc234348 |
| nsc-234348 |
| ml 1024 |
| theofibrate |
| 54504-70-0 |
| propionic acid, 2-(7-theophyllinyl)ethyl ester |
| propanoic acid, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7h-purin-7-yl)ethyl ester |
| 2-(p-chlorophenoxy)-2-methylpropionic acid 2-(7-theophyllinyl)ethyl ester |
| 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7h-purin-7-yl)ethyl 2-[(4-chlorophenyl)oxy]-2-methylpropanoate |
| etofylline clofibrate |
| 1-(7-theophyllinyl)-2-ethyl (2-(p-chlorophenoxy)isobutyrate) |
| clofibrate d'etofylline [inn-french] |
| theofibrate [usan] |
| einecs 259-191-6 |
| propionic acid, 2-(4-chlorophenoxy)-2-methyl-, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7h-purin-7-yl) ethyl ester |
| nsc 234348 |
| etofyllinclofibrate |
| 2-(p-chlorophenoxy)-2-methylpropionic acid, ester with 7-(2-hydroxyethyl)theophylline |
| 1-(theophyllin-7-yl)-ethyl-2-(2-(p-chlorophenoxy)-2-methylpropionate) |
| brn 1233286 |
| propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7h-purin-7-yl)ethyl ester |
| etofyllinclofibrat [german] |
| 1-(theophyllin-7-yl)-ethyl-2 2-(p-chlorophenoxy)-2-methylpropionate |
| 1-(theophyllin-7-yl)-aethyl-2 2-(p-chlorphenoxy)-2-methylpropionat [german] |
| etofyllini clofibras [inn-latin] |
| clofibrato de etofilina [inn-spanish] |
| duolip (tn) |
| theofibrate (usan) |
| D06102 |
| etofylline clofibrate (inn) |
| ml-1024 |
| duolip |
| etofilline clofibrate |
| NCGC00160455-01 |
| CHEBI:135681 |
| smr001830757 |
| AKOS001359046 |
| dtxsid0023032 , |
| tox21_111825 |
| dtxcid003032 |
| cas-54504-70-0 |
| CHEMBL1318939 |
| clofibrate etofylline |
| unii-14uh1jqp6l |
| clofibrato de etofilina |
| etofyllinclofibrat |
| clofibrate d'etofylline |
| 14uh1jqp6l , |
| 1-(theophyllin-7-yl)-aethyl-2 2-(p-chlorphenoxy)-2-methylpropionat |
| etofylline clofibrate [inn] |
| etofyllini clofibras |
| FT-0630670 |
| theofibrate [mi] |
| etofylline clofibrate [mart.] |
| etofylline clofibrate [who-dd] |
| SCHEMBL49272 |
| MLS006011490 |
| KYAKGJDISSNVPZ-UHFFFAOYSA-N |
| 1-(7-theophyllinyl)-2-ethyl [2-(p-chlorophenoxy)-isobutyrate] |
| 1-(7-theophyllinyl)-2-ethyl(2-(p-chlorophenoxy)isobutyrate) |
| W-105616 |
| Z51093246 |
| etofylline-clofibrate |
| CS-0028192 |
| HY-107348 |
| Q27251653 |
| MS-27388 |
| EN300-190670 |
| 2-(1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1h-purin-7-yl)ethyl 2-(4-chlorophenoxy)-2-methylpropanoate |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic parameters of the metabolites after oral application of 2 capsules Duolip, corresponding to 500 mg etofylline clofibrate, were evaluated in 7 healthy volunteers." | ( [Metabolism and pharmacokinetics of etofylline clofibrate, new antilipemic]. Donike, M; Erking, W; Lücker, PW; Wetzelsberger, K, 1980) | 0.74 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
The patients were given etofylline clofibrate in a dosage of 500 mg/day (2x1 capsule) over 4 weeks, and 750 mg/ day (3 x 1 capsule) for further 4 months. In type IIa etoypfibrate shows a good effect on total cholesterol and on the cholesterol fractions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All patients were dietary adapted before the preliminary wash-out period of 4 weeks and received etofylline clofibrate in a dosage of 500 mg/day (2x1 capsule) over 4 weeks, and 750 mg/day (3 x 1 capsule) over further 4 months." | ( [Clinical effects and tolerance of etofylline clofibrate]. Metz, G; Specker, M; Ziegler, WJ, 1980) | 0.76 |
| " In type IIa etofylline clofibrate shows a good effect on total cholesterol and on the cholesterol fractions, both with regard to the collective treated and to the low dosage of 750 mg/d etofylline clofibrate compared to the usual dosage of 1500 mg clofibrate." | ( [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)]. Hausmann, L; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) | 0.96 |
| Class | Description |
|---|---|
| oxopurine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| USP1 protein, partial | Homo sapiens (human) | Potency | 251.1890 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| TDP1 protein | Homo sapiens (human) | Potency | 31.2956 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| AR protein | Homo sapiens (human) | Potency | 25.5429 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743042; AID743054 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 26.8308 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743079; AID743080; AID743091 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 32.1968 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 33.4915 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 1.5849 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 19 (52.78) | 18.7374 |
| 1990's | 10 (27.78) | 18.2507 |
| 2000's | 1 (2.78) | 29.6817 |
| 2010's | 4 (11.11) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.55) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (10.81%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 33 (89.19%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||